Lantheus appoints Minnie Baylor-Henry to Board of Directors

Lantheus Holdings, Inc.

Ms. Baylor-Henry, an expert in FDA regulatory affairs, appointed as Class II independent director effective March 1, 2022.
Will serve on the Compensation Committee and Science and Technology Committee.
Board now comprises nine directors, eight of whom are independent.
Compensation includes $55,000/yr cash, $25,833 initial RSU grant, and $155,000 annual RSU grant.
She previously served at FDA, Johnson & Johnson, and Deloitte; also on boards of APYX, PRTK, SCPH.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Minnie Baylor-Henry

Director

LNTH · Lantheus Holdings, Inc.

Effective: 2022-03-01
Filed: March 1, 2022, 6:59 PM ET

On March 1, 2022, Lantheus Holdings, Inc. (“Lantheus”) appointed Ms. Minnie Baylor-Henry, a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus’ Board of Directors (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Minnie Baylor-Henry was appointed as Director at Lantheus Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 1, 2022, Lantheus Holdings, Inc. (“Lantheus”) appointed Ms. Minnie Baylor-Henry, a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus’ Board of Directors (the “Board”).

View on SEC.gov

Lantheus Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-061322

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.